Highbury Group

About The Fund

Highbury Group is an investment fund that operates at the intersection of several high-growth and innovation-driven industries. With a deep focus on sectors such as BioTech, CleanTech, A.I. (and Big Data), HealthTech (and Fitness), Medical Devices (and Hospital Services), Healthcare (and Wellness), Consumer, and Pharmaceuticals (and Medicine), they actively invest in startups and companies that have the potential to drive significant advancements in these fields. Highbury Group is particularly notable for its involvement in the early to mid-stages of company development, specializing in Seed, Series A, and Series B funding rounds. With a minimum investment of $500,000 and a maximum of $50,000,000, they are able to cater to a wide range of funding requirements, ideally targeting an investment sweet spot of around $10,000,000. Their investment philosophy is driven by the ambition to partner with entrepreneurs who use science and technology to build companies that not only thrive commercially but also contribute to human health and the betterment of humanity in substantial and enduring ways. Through their investments, Highbury Group seeks to support groundbreaking work such as the world's first inhaled TB vaccine among other innovations. They pride themselves on a track record of successful exits and partnerships with over 15 billion-dollar companies, which clearly demonstrates their expertise and effectiveness as an investment partner in the health and technology sectors. Some of the notable exits from their investment portfolio include Anacor Pharmaceuticals (acquired by Pfizer for $5.2B), Visterra (acquired by $430M), Slack (acquired by Salesforce for $27.7B), Guardant Health (NASDAQ: GH), Singular Genomics (NASDAQ: OMIC), and Science.io (acquired by Veradigm).